These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 25097033)

  • 21. RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation.
    Holderfield M; Merritt H; Chan J; Wallroth M; Tandeske L; Zhai H; Tellew J; Hardy S; Hekmat-Nejad M; Stuart DD; McCormick F; Nagel TE
    Cancer Cell; 2013 May; 23(5):594-602. PubMed ID: 23680146
    [TBL] [Abstract][Full Text] [Related]  

  • 22. KIT Suppresses BRAF
    Neiswender JV; Kortum RL; Bourque C; Kasheta M; Zon LI; Morrison DK; Ceol CJ
    Cancer Res; 2017 Nov; 77(21):5820-5830. PubMed ID: 28947418
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma.
    Yang R; Piperdi S; Gorlick R
    Clin Cancer Res; 2008 Oct; 14(20):6396-404. PubMed ID: 18927278
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Flagellin and lipopolysaccharide stimulate the MEK-ERK signaling pathway in chicken heterophils through differential activation of the small GTPases, Ras and Rap1.
    Kogut MH; Genovese KJ; He H
    Mol Immunol; 2007 Mar; 44(7):1729-36. PubMed ID: 17045653
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative effects of insulin on the activation of the Raf/Mos-dependent MAP kinase cascade in vitellogenic versus postvitellogenic Xenopus oocytes.
    Chesnel F; Bonnec G; Tardivel A; Boujard D
    Dev Biol; 1997 Aug; 188(1):122-33. PubMed ID: 9245517
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma.
    Yen I; Shanahan F; Lee J; Hong YS; Shin SJ; Moore AR; Sudhamsu J; Chang MT; Bae I; Dela Cruz D; Hunsaker T; Klijn C; Liau NPD; Lin E; Martin SE; Modrusan Z; Piskol R; Segal E; Venkatanarayan A; Ye X; Yin J; Zhang L; Kim JS; Lim HS; Kim KP; Kim YJ; Han HS; Lee SJ; Kim ST; Jung M; Hong YH; Noh YS; Choi M; Han O; Nowicka M; Srinivasan S; Yan Y; Kim TW; Malek S
    Nature; 2021 Jun; 594(7863):418-423. PubMed ID: 33953400
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Different Raf protein kinases mediate different signaling pathways to stimulate E3 ligase RFFL gene expression in cell migration regulation.
    Gan X; Wang C; Patel M; Kreutz B; Zhou M; Kozasa T; Wu D
    J Biol Chem; 2013 Nov; 288(47):33978-33984. PubMed ID: 24114843
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Limited Proteolysis Combined with Stable Isotope Labeling Reveals Conformational Changes in Protein (Pseudo)kinases upon Binding Small Molecules.
    Di Michele M; Stes E; Vandermarliere E; Arora R; Astorga-Wells J; Vandenbussche J; van Heerde E; Zubarev R; Bonnet P; Linders JT; Jacoby E; Brehmer D; Martens L; Gevaert K
    J Proteome Res; 2015 Oct; 14(10):4179-93. PubMed ID: 26293246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optogenetically controlled RAF to characterize BRAF and CRAF protein kinase inhibitors.
    Chatelle CV; Hövermann D; Müller A; Wagner HJ; Weber W; Radziwill G
    Sci Rep; 2016 Mar; 6():23713. PubMed ID: 27025703
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.
    Henry JR; Kaufman MD; Peng SB; Ahn YM; Caldwell TM; Vogeti L; Telikepalli H; Lu WP; Hood MM; Rutkoski TJ; Smith BD; Vogeti S; Miller D; Wise SC; Chun L; Zhang X; Zhang Y; Kays L; Hipskind PA; Wrobleski AD; Lobb KL; Clay JM; Cohen JD; Walgren JL; McCann D; Patel P; Clawson DK; Guo S; Manglicmot D; Groshong C; Logan C; Starling JJ; Flynn DL
    J Med Chem; 2015 May; 58(10):4165-79. PubMed ID: 25965804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RAF inhibitors that evade paradoxical MAPK pathway activation.
    Zhang C; Spevak W; Zhang Y; Burton EA; Ma Y; Habets G; Zhang J; Lin J; Ewing T; Matusow B; Tsang G; Marimuthu A; Cho H; Wu G; Wang W; Fong D; Nguyen H; Shi S; Womack P; Nespi M; Shellooe R; Carias H; Powell B; Light E; Sanftner L; Walters J; Tsai J; West BL; Visor G; Rezaei H; Lin PS; Nolop K; Ibrahim PN; Hirth P; Bollag G
    Nature; 2015 Oct; 526(7574):583-6. PubMed ID: 26466569
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF.
    Hu J; Yu H; Kornev AP; Zhao J; Filbert EL; Taylor SS; Shaw AS
    Proc Natl Acad Sci U S A; 2011 Apr; 108(15):6067-72. PubMed ID: 21441104
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RAF-MEK-ERK pathway in cancer evolution and treatment.
    Ullah R; Yin Q; Snell AH; Wan L
    Semin Cancer Biol; 2022 Oct; 85():123-154. PubMed ID: 33992782
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activation and role of MAP kinase-dependent pathways in retinal pigment epithelial cells: ERK and RPE cell proliferation.
    Hecquet C; Lefevre G; Valtink M; Engelmann K; Mascarelli F
    Invest Ophthalmol Vis Sci; 2002 Sep; 43(9):3091-8. PubMed ID: 12202534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CRAF dimerization with ARAF regulates KRAS-driven tumor growth.
    Venkatanarayan A; Liang J; Yen I; Shanahan F; Haley B; Phu L; Verschueren E; Hinkle TB; Kan D; Segal E; Long JE; Lima T; Liau NPD; Sudhamsu J; Li J; Klijn C; Piskol R; Junttila MR; Shaw AS; Merchant M; Chang MT; Kirkpatrick DS; Malek S
    Cell Rep; 2022 Feb; 38(6):110351. PubMed ID: 35139374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.
    Marzec M; Kasprzycka M; Liu X; Raghunath PN; Wlodarski P; Wasik MA
    Oncogene; 2007 Feb; 26(6):813-21. PubMed ID: 16909118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An enzyme-linked immunosorbent assay for the Raf/MEK1/MAPK signaling cascade.
    Mallon R; Feldberg LR; Kim SC; Collins K; Wojciechowicz D; Hollander I; Kovacs ED; Kohler C
    Anal Biochem; 2001 Jul; 294(1):48-54. PubMed ID: 11412005
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations.
    Tran G; Huynh TN; Paller AS
    J Am Acad Dermatol; 2018 Mar; 78(3):579-590.e4. PubMed ID: 29107340
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elastin peptides activate extracellular signal-regulated kinase 1/2 via a Ras-independent mechanism requiring both p110gamma/Raf-1 and protein kinase A/B-Raf signaling in human skin fibroblasts.
    Duca L; Lambert E; Debret R; Rothhut B; Blanchevoye C; Delacoux F; Hornebeck W; Martiny L; Debelle L
    Mol Pharmacol; 2005 Apr; 67(4):1315-24. PubMed ID: 15653554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.